Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 17, 2026
Why Is AirSculpt Technologies (AIRS) Stock Down -11.37% Today?

Why Is AirSculpt Technologies (AIRS) Stock Down -11.37% Today?

Key Takeaways

  • Shares of AIRS fell 11.37% to $3.04 in Monday trading, down $0.39 from Friday’s close of $3.43.
  • The decline extends post-earnings turbulence following the company’s August 10 second-quarter report.
  • Q2 revenue of $42.9 million missed consensus and fell 3% year over year; the full-year adjusted EBITDA outlook was cut to $12–$14 million.
  • No fresh company-specific announcement was apparent during Monday’s slide, pointing to technical and sentiment-driven selling.
  • Traders are watching the $3.00 area and upcoming Q3 case-volume and margin trends.

Opening Summary

AirSculpt Technologies, Inc. (AIRS) is a provider of minimally invasive body contouring procedures in the United States and Canada. In Monday afternoon trading, shares dropped 11.37% to $3.04, compared with Friday’s close of $3.43. The decline extended a period of elevated volatility that began when the company reported second-quarter results on August 10, and the market’s immediate focus remained on the weaker profitability outlook rather than on any new corporate announcement.

Q2 Results and Lowered Profit Outlook

The primary overhang on AIRS remains the second-quarter report released before the market open on August 10. Revenue came in at $42.9 million, down 3% from $44.0 million a year earlier and below the consensus estimate of roughly $44.2 million. Net loss widened to $1.1 million from $0.6 million in the prior-year period, while adjusted EBITDA declined to $4.9 million from $5.8 million.

Management reaffirmed full-year revenue guidance but said results are expected to track toward the lower end of the $151 million-to-$157 million range. More importantly for investor sentiment, the company reduced its full-year adjusted EBITDA guidance to $12 million-to-$14 million. That downward revision to profitability expectations has kept selling pressure on the stock even after the initial post-earnings reaction.

Technical Selling and Post-Earnings Volatility

The stock’s recent path illustrates how volatile AIRS has become. The shares closed at $5.01 on August 7, then collapsed to $2.75 on August 10 after the earnings release. A partial recovery followed over the next four sessions, lifting the stock back to $3.43 by August 14. Monday’s slide to $3.04 unwound most of that rebound in a single session.

With a beta near 2.4 and a relatively small float, AIRS is prone to outsized intraday moves. The absence of a fresh company-specific catalyst during Monday’s decline suggests that the move was driven by continued digestion of the lowered earnings outlook, profit-taking after last week’s bounce, and momentum-driven selling once the shares surrendered key short-term support.

Market Context and Trading Activity

Turnover in AIRS has been elevated relative to early-August levels since the earnings report. Daily volume surged to roughly 2.5 million shares on August 10 and remained well above the early-August baseline in subsequent sessions, reflecting intense two-way trading as investors repositioned.

The selling on Monday appeared largely company-specific rather than tied to a broad market catalyst. The stock’s slide below the $3.30 level and toward $3.00 placed it back near the lower end of its recent post-earnings range, a technical breakdown that likely contributed to additional selling pressure during the afternoon.

What Comes Next for AIRS

Investors will be watching whether AIRS can stabilize above the $3.00 level or whether the post-earnings range continues to compress. The next scheduled quarterly report is expected in November, and management commentary on same-center case volumes, revenue per case, and adjusted EBITDA margins will be central to the investment debate.

Additional focus areas include the rollout of newer procedures such as skin tightening and skin removal, the planned AlloClae pilot, demand trends among GLP-1 patients, and progress on debt refinancing. Consumer spending on elective cosmetic procedures remains a key macroeconomic risk, and the company’s ability to convert higher marketing investment into sustained case growth will likely determine whether the recent volatility gives way to a more durable trend.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to explore automated approaches tailored to different market environments. Investors seeking a data-driven way to monitor opportunities across active tickers may find the section a useful starting point.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AIRS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


AIRS's RSI Oscillator recovers from oversold territory

The RSI Oscillator for AIRS moved out of oversold territory on August 11, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 52 cases where AIRS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AIRS advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

AIRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AIRS as a result. In of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AIRS turned negative on August 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

AIRS moved below its 50-day moving average on August 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AIRS crossed bearishly below the 50-day moving average on August 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AIRS entered a downward trend on July 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AIRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.359) is normal, around the industry mean (238.711). P/E Ratio (196.563) is within average values for comparable stocks, (131.068). AIRS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.749). AIRS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.014). P/S Ratio (1.502) is also within normal values, averaging (2.693).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 4.79B. The market cap for tickers in the group ranges from 48.5K to 87.61B. HCA holds the highest valuation in this group at 87.61B. The lowest valued company is BYZN at 48.5K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was 0%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 43%. AVAH experienced the highest price growth at 30%, while AIRS experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was -20%. For the same stocks of the Industry, the average monthly volume growth was -19% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 50
Price Growth Rating: 50
SMR Rating: 65
Profit Risk Rating: 88
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
AIRS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Profile
Details
Industry
N/A
Address
1111 Lincoln Road
Phone
+1 786 709-9690
Employees
453
Web
https://www.airsculpt.com
Interact to see
Advertisement
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Cincinnati Financial (CINF) reports Q4 2025 earnings on February 9, 2026, after market close, with consensus EPS of $2.86–$2.89 and revenue around $2.91 billion. Allstate (ALL) recently reported Q4 2025 EPS of $14.31, well above the $8.72 estimate, with revenue of $17.3 billion on February 4, 2026.
Gilead Sciences (GILD): Q4 2025 earnings due February 10, consensus EPS $1.83, revenue $7.68B. Growth driven by HIV franchise; oncology investments like Trodelvy may offer upside. Amgen (AMGN): Reported Q4 2025 EPS $5.29 vs $4.73 expected, revenue $9.9B (+9% YoY). Strong 2026 guidance: $37–38.4B revenue, $21.60–23.00 non-GAAP EPS.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
CME Group delivered record 2025 revenue of $6.52 billion, up 6% year-over-year. Q4 adjusted EPS of $2.77 exceeded expectations.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Q4 2025 revenue reached $12.5 billion, exceeding expectations, with growth portfolio sales up 16% year-over-year. Full-year 2025 revenue totaled $48.2 billion, supported by Eliquis, Opdivo, and newer products including Breyanzi and Camzyos.
KKR reported Q4 2025 adjusted EPS of $1.12, slightly below the $1.14 consensus estimate. The firm raised a record $129 billion in 2025, surpassing 80% of its $300 billion fundraising goal for 2024–2026.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.